Rise in prevalence of ulcerative colitis and Crohn's disease, growing awareness of the disease across the world, drives the growth of the market David Correa Allied Market Research + 1 800-792-5285 ...
February is heart month. Almost all heart attacks are preventable, but in spite of that they remain the number one cause of ...
An international study led by the University of Oulu and Oulu University Hospital has identified six genetic regions ...
The method could be used to develop a blood test to identify inflammatory-bowel-disease patients most at risk.
Experts hope to create a blood test to see which patients with inflammatory bowel disease are most at risk of bowel cancer.
Coherus BioSciences, Inc.’s CHRS share price has surged by 10.66%, which has investors questioning if this is right time to sell.
Shares of Teva Pharmaceutical Industries ( TEVA -13.66%) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p ...
The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...
Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating ...
Three players in the biosimilar space have already sparked hope for the new year, with each having big business or regulatory ...
Research analysts at William Blair decreased their FY2025 earnings per share (EPS) estimates for shares of AbbVie in a note ...
For many individuals, the term “ostomy” may be unfamiliar, yet it represents a life-changing procedure that offers critical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback